CMS

CMS demo could pave the path to eliminating Part D rebates
CMS demo could pave the path to eliminating Part D rebates
BioCentury
CMS
drug pricing
Medicare Part D
drug rebates
Flag link:
Electronic Health Records: A Promising New Way To Fight the Opioid Epidemic
Electronic Health Records: A Promising New Way To Fight the Opioid Epidemic
Forbes
opioids
opioid crisis
EHRs
EMRs
CMS
Flag link:
Drug spending could rise 6.1 percent annually by 2020, federal projections show
Drug spending could rise 6.1 percent annually by 2020, federal projections show
Stat
drug spending
CMS
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
Governor moves to boost California's drug price bargaining power
Governor moves to boost California's drug price bargaining power
BioCentury
drug pricing
CMS
Medicaid
California
Flag link:
CMS rule cuts reimbursement for new Part B drugs
CMS rule cuts reimbursement for new Part B drugs
BioCentury
Medicare Part B
CMS
reimbursement
physician-administered drugs
Flag link:
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
Fierce Pharma
CMS
UnitedHealthcare
Medicare
JNJ
Remicade
biosimilars
Pfizer
Merck
Flag link:
Medtech reporting would change under new opioid law
Medtech reporting would change under new opioid law
Mass Device
opioids
opioid crisis
Medicare
Medicaid
CMS
devices
Flag link:
Standardization Of Drug Compendia That Support Off-Label Use Reimbursement Of Cancer Drugs
Standardization Of Drug Compendia That Support Off-Label Use Reimbursement Of Cancer Drugs
Forbes
off-label
oncology
oncologists
cancer
CMS
Flag link:
Medicare Part D to allow indication-driven formularies
Medicare Part D to allow indication-driven formularies
BioCentury
Medicare
Medicare Part D
CMS
formulary
Flag link:
No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds say
No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds say
Fierce Pharma
drug pricing
Massachusetts
Medicaid
CMS
PBMs
Flag link:
Pharma, payers clash over CMS Part D drug rebate plan
Pharma, payers clash over CMS Part D drug rebate plan
HealthcareDive
payers
CMS
Medicare Part D
Medicare
drug rebates
Flag link:
Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B
Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B
RAPS.org
AbbVie
Amgen
Humira
biosimilars
Medicare
Medicaid
CMS
Flag link:
Why regional reimbursement strategies could be right for medtech
Why regional reimbursement strategies could be right for medtech
Medical Design and Outsourcing
devices
reimbursement
CMS
Flag link:
Health Spending Projections By CMS Could Influence AHCA Votes
Health Spending Projections By CMS Could Influence AHCA Votes
Forbes
healthcare reform
CMS
American Health Care Act
Flag link:
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Seeking Alpha
Mylan Labs
EpiPens
CMS
rebates
Medicare
Medicaid
Flag link:
CMS Releases Final Medicaid Rebate Rule
CMS Releases Final Medicaid Rebate Rule
FDA Law Blog
Medicaid
CMS
rebates
Flag link:
A proposal for biosimilar reimbursement sparks outrage
A proposal for biosimilar reimbursement sparks outrage
Pharmalot
biosimilars
CMS
reimbursement
Flag link:
Dendreon And CMS Under SEC Scrutiny Over Insider Trading
Dendreon And CMS Under SEC Scrutiny Over Insider Trading
Bidness Etc.
Dendreon
CMS
SEC
insider trading
Flag link:
Pharma, Physicians And 'Open Payments': Moving From Data To Understanding
Pharma, Physicians And 'Open Payments': Moving From Data To Understanding
Forbes
CMS
physician payments
Physician Payment Sunshine Act
Flag link:

Pages